ImetelChat

- IMerge contains already a Phase 3 protocol. The primary outcome is TI. IMegre is intended clearly as a registration enabling study. Expecting to see significant proportion of TI as well as symptomatic improvement. - the decisive argument for Tefferi as well as JnJ to put their cards on imetelstat ...

Thanks for registering, Phil! Please feel free to provide your opinions and views here!

Zacks, 8 Dec 2015: Geron’s telomerase technology platform represents significant commercial opportunity. The successful development of products that target telomeres could very well change the treatment paradigm for several diseases including oncology, which represents significant commercial potenti...

Dr. Titia de Lange from the Rockefeller University Institute Australia speaks about telomeres and telomerase (recorded 30 May 2015). It is very nice and clear explanation. She speaks about the mechanisms of telomerase, including ageing. On 21.13 she elaborates on telomerase inhibition as a cancer th...

Hi BioPearl, thanks for registering and your supportive post. I hope this board will have good discussions and contributions. I will check DewDillegence as you suggest. I am looking forward to see how this board will evolve. Patients, investors, doctors and anyone interested should be safe and comfo...

by sdrawkcabeman (repost from Yahoo MB, 6 Dec 2015 1:12 PM) Points to drive home from the presentation The emphasis and growing chorus is that there’s a serious unmet need for MF/MDS/AML pts, and that’s the big push coalescing behind Imet. In the Q&A Dr. Baerlocher, Dr. Burington, Dr. Scarlett all s...

7 Dec 2015 Piper Jaffray on Monday issued a company note on Geron Corporation (NASDAQ: GERN) after news of new drug developments at the ASH 2015 conference. Piper Jaffray rates Geron as Overweight and raised the company's price target from $5.00 to $10.00. Analysts Charles Duncan and Sarah Weber wro...

MDS trial IMerge (34 locations) is no recruiting at two locations: Bethesda (Maryland, US) and Groningen (Netherlands). From the clinical trials site: Updated Nov. 30th Clinical Trials Identifier: NCT02598661 ( imetelstat Phase 2/3 ) Now Recruiting 2 locations - Recruiting Bethesda, Maryland, United...

John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015. The live and archived webcast will be available at http://www.veracast.com/webcasts/opco/healthcare2015/84203554236...